share_log

Novo-Nordisk A/S | 6-K: Novo Nordisk A/S - Share Repurchase Programme

SEC announcement ·  Mar 4 10:55
Summary by Moomoo AI
Novo Nordisk A/S, a leading global healthcare company, has announced the continuation of its share repurchase program, which began on February 6, 2024. The program, compliant with the European Union's Market Abuse Regulation (MAR) and Safe Harbour Rules, is part of a larger 12-month buyback plan to repurchase shares worth up to DKK 20 billion. From February 26, 2024, to March 1, 2024, Novo Nordisk bought back 824,500 B shares at an average price of DKK 836.80 per share, totaling DKK 689,940,585. The transactions are part of a scheduled repurchase running until April 30, 2024, with a target of DKK 2.1 billion for this period. Following these purchases, Novo Nordisk holds 47,365,207 B shares as treasury shares, representing 1.1% of the share capital. The company, with a rich history dating back to 1923, is committed to combating serious chronic diseases and employs approximately 63,400 people across 80 countries. Novo Nordisk's shares are traded on Nasdaq Copenhagen and its ADRs on the New York Stock Exchange.
Novo Nordisk A/S, a leading global healthcare company, has announced the continuation of its share repurchase program, which began on February 6, 2024. The program, compliant with the European Union's Market Abuse Regulation (MAR) and Safe Harbour Rules, is part of a larger 12-month buyback plan to repurchase shares worth up to DKK 20 billion. From February 26, 2024, to March 1, 2024, Novo Nordisk bought back 824,500 B shares at an average price of DKK 836.80 per share, totaling DKK 689,940,585. The transactions are part of a scheduled repurchase running until April 30, 2024, with a target of DKK 2.1 billion for this period. Following these purchases, Novo Nordisk holds 47,365,207 B shares as treasury shares, representing 1.1% of the share capital. The company, with a rich history dating back to 1923, is committed to combating serious chronic diseases and employs approximately 63,400 people across 80 countries. Novo Nordisk's shares are traded on Nasdaq Copenhagen and its ADRs on the New York Stock Exchange.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more